Download - NNE Pharmaplan company presentation
![Page 1: NNE Pharmaplan company presentation](https://reader033.vdocuments.net/reader033/viewer/2022061211/5492a113ac7959182e8b4682/html5/thumbnails/1.jpg)
Engineering for a healthier world
![Page 2: NNE Pharmaplan company presentation](https://reader033.vdocuments.net/reader033/viewer/2022061211/5492a113ac7959182e8b4682/html5/thumbnails/2.jpg)
2
USA. A blood transfusion is vitalat some point in the treatment of
5 million patients each year.
CZECH REPUBLIC. Fresenius Hemocarehas just revamped their facility,
which manufactures blood bags.
Our company film
![Page 3: NNE Pharmaplan company presentation](https://reader033.vdocuments.net/reader033/viewer/2022061211/5492a113ac7959182e8b4682/html5/thumbnails/3.jpg)
Where we come from1930s – Danish Novo and Nordisk Gentofte (later Novo Nordisk) employed the first engineers.
1974 - Pharmaplan was founded as part of the medical care group by Fresenius, Germany.
1991 - After functioning as in-house consultants at Novo Nordisk for years, NNE (Novo Nordisk Engineering A/S) demerged as an independent company.
2007 - Acquisition of Pharmaplan, a company similar to NNE in DNA.NNE Pharmaplan was founded.
With 80 years of experience we are passionate about our services to the pharma and biotech industries.
4
Recent awards 2004 IChemE: “Haden Freeman Award for Engineering Excellence”2005 ISPE Facility of the Year Award winner – Novo Nordisk’s NovoSeven (FVII) facility2008 ISPE Company of the Year winner2009 ISPE Facility of the Year Award winner – Facility Integration – hameln pharmaceuticals, Germany2009 ISPE Facility of the Year Award winner – Operational Excellence – R&D division of US biotech company, Switzerland2009 Emerson: “PlantWeb Excellence” for DeltaV application for Pronova BioPharma project (KalOmega)
![Page 4: NNE Pharmaplan company presentation](https://reader033.vdocuments.net/reader033/viewer/2022061211/5492a113ac7959182e8b4682/html5/thumbnails/4.jpg)
Who we are
We are the leading consulting and engineering company in the complex field of pharma and biotech.
We count close to 1,700 professionals with project experience and knowledge related to pharma and biotech. More than 200 have hands-on development or production experience.
We executed 2,667 projects in 2010.
5
Our project execution and our staff
embody 10,000 years of
experience within pharma and biotech
![Page 5: NNE Pharmaplan company presentation](https://reader033.vdocuments.net/reader033/viewer/2022061211/5492a113ac7959182e8b4682/html5/thumbnails/5.jpg)
Our future outlook
6
We want to be the leading international supplier of projects, engineering and consulting services to the pharma and biotech industries.
We advise organisations
such asISPE, PDA, ISO, FDA, SFDA, EMA
and WHO
![Page 6: NNE Pharmaplan company presentation](https://reader033.vdocuments.net/reader033/viewer/2022061211/5492a113ac7959182e8b4682/html5/thumbnails/6.jpg)
Our work split
7
We have a 91% customer satisfaction
rate. We are very proud of this fact.
The main part of our employees have a background in pharmaceutical production companies.
![Page 7: NNE Pharmaplan company presentation](https://reader033.vdocuments.net/reader033/viewer/2022061211/5492a113ac7959182e8b4682/html5/thumbnails/7.jpg)
Closer to our customers
We employ close to 1,700 people at more than 25 locations in 11 countries around the world.
8
97% of our revenues
come from the pharma and biotech
industries
![Page 8: NNE Pharmaplan company presentation](https://reader033.vdocuments.net/reader033/viewer/2022061211/5492a113ac7959182e8b4682/html5/thumbnails/8.jpg)
Global reach – local knowledge
9
Certifications:ISO 9001 Worldwide
ISO 14001OHSAS 18001
![Page 9: NNE Pharmaplan company presentation](https://reader033.vdocuments.net/reader033/viewer/2022061211/5492a113ac7959182e8b4682/html5/thumbnails/9.jpg)
Optimal production processes
10
Company revenue
2010USD 279M EUR 197M
DEVELOP ESTABLISH IMPROVE
Projectdevelopment
Process & Productdevelopment
Investment projectCD / BD / DD / CON / C&Q
Optimisation, training, revamps,GAP analysis, operational support
![Page 10: NNE Pharmaplan company presentation](https://reader033.vdocuments.net/reader033/viewer/2022061211/5492a113ac7959182e8b4682/html5/thumbnails/10.jpg)
Our services
11
![Page 11: NNE Pharmaplan company presentation](https://reader033.vdocuments.net/reader033/viewer/2022061211/5492a113ac7959182e8b4682/html5/thumbnails/11.jpg)
Single use
With single-use technology you get maximum flexibility, fast change-over, no cross-contamination between productsand a lower investment cost.
12
![Page 12: NNE Pharmaplan company presentation](https://reader033.vdocuments.net/reader033/viewer/2022061211/5492a113ac7959182e8b4682/html5/thumbnails/12.jpg)
Risk-based approach and Quality by Design
The answer to how you can avoid low-yield production or losing a batch.
13
![Page 13: NNE Pharmaplan company presentation](https://reader033.vdocuments.net/reader033/viewer/2022061211/5492a113ac7959182e8b4682/html5/thumbnails/13.jpg)
Fast-track
In traffic, fast is not a virtue. In pharmaceutical engineering we believe it is. And we have pushed the limits many times.
14
![Page 14: NNE Pharmaplan company presentation](https://reader033.vdocuments.net/reader033/viewer/2022061211/5492a113ac7959182e8b4682/html5/thumbnails/14.jpg)
Automation and IT
Automation & IT are key to obtaining competitive advantages by achieving faster, more efficient delivery at lower costs without compromising flexibility and quality.
15
![Page 15: NNE Pharmaplan company presentation](https://reader033.vdocuments.net/reader033/viewer/2022061211/5492a113ac7959182e8b4682/html5/thumbnails/15.jpg)
Multiproduct revamps
Revamping your production allows you to safely increase production capacity while postponing large investments.
16
![Page 16: NNE Pharmaplan company presentation](https://reader033.vdocuments.net/reader033/viewer/2022061211/5492a113ac7959182e8b4682/html5/thumbnails/16.jpg)
ASTM E2500 verification
ASTM E2500 is referred to as the validation of the future. How much money can it save you?
17
![Page 17: NNE Pharmaplan company presentation](https://reader033.vdocuments.net/reader033/viewer/2022061211/5492a113ac7959182e8b4682/html5/thumbnails/17.jpg)
Personalised drugs and treatment
The general trend moves away from ‘blockbuster’ drugs to more personalised drugs, presenting completely new challenges to pharma companies.
18
![Page 18: NNE Pharmaplan company presentation](https://reader033.vdocuments.net/reader033/viewer/2022061211/5492a113ac7959182e8b4682/html5/thumbnails/18.jpg)
Turnkey facilities
A turnkey solution will save you the trouble of dealing with multiple suppliers – you get everything from a single source.
19
![Page 19: NNE Pharmaplan company presentation](https://reader033.vdocuments.net/reader033/viewer/2022061211/5492a113ac7959182e8b4682/html5/thumbnails/19.jpg)
Cost-effective operation and facilities
Cost-effective production is a must to survive in the highly competitive pharma market. Evolution calls for operational excellence, and we can help you get to the next level.
20